BCL2L1 and neoplasm: In PDX models, combining dinaciclib with cisplatin synergistically reduced tumor volume, and extended survival compared to monotherapies, highlighting the therapeutic potential.<h4>Conclusion</h4>This study elucidates the epigenetic and transcriptional mechanisms driving the CDK1-SOX9-BCL-xL axis in gastric cancer chemoresistance.